Abstract
E5564 (α-d-glucopyranose) is a synthetic antagonist of bacterial endotoxin that has been shown to completely block human endotoxin response. Low doses of E5564 (0.35-3.5 mg) have a long pharmacokinetic half-life, but a surprisingly short ex vivo and in vivo pharmacodynamic half-life (generally less than several hours). To determine whether extended antagonistic activity can be achieved in vivo, this study assesses the pharmacodynamic activity of 4- and 72-h infusions of E5564 into normal volunteers. Administration of 3.5 mg of E5564/h × 72 h completely blocked effects of endotoxin challenge at the end of dosing (72 h), and at 48 and 72 h postdosing. Similarly, a 4-h infusion of E5564, 3 mg/h completely blocked endotoxin administered 8 h postdosing. A lower dose of E5564, 0.5 mg/h × 4 h, ameliorated but did not block most effects of endotoxin 8 h postdosing (p <0.05). Finally, the effect of varying plasma lipoprotein content on E5564 activity was studied in subjects having high or low cholesterol levels (>180 or <140 mg/dl) after 72-h infusion of 252 mg of E5564. No differences were observed. These results demonstrate that E5564 blocks the effects of endotoxin in a human model of clinical sepsis and indicate its potential in the treatment and/or prevention of clinical sepsis.
Footnotes
-
This study was designed and funded by Eisai Medical Research Inc. (Teaneck, NJ). Portions of this study have been presented at the 14th World Congress of Pharmacology, San Francisco, CA, July 7-12, 2002, abstract 91.
-
DOI: 10.1124/jpet.103.056531.
-
ABBREVIATIONS:E5564, α-d-glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono-β-d-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate), tetrasodium salt; CAS Registry No. 185954-98-7; LPS, lipopolysaccharide; PD, pharmacodynamic; PK, pharmacokinetic; HDL, high-density lipoprotein; AE, adverse event; WBC, white blood cell; ANOVA, analysis of variance; AUC, area under the curve; bpm, beats per minute; TNF, tumor necrosis factor; IL, interleukin.
-
↵† Deceased.
- Received July 3, 2003.
- Accepted September 25, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|